Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 14/20 | 0.61 |
| ▸ | ADCY8 | P40145 | 11/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23160948 | 0.85 | ADCY1 (0.74) | ADCY1ADCY8HTR2BHTTKDM4E | |
| SCHEMBL23160963 | 0.85 | ADCY1 (0.74) | ADCY1ADCY8HTR2BHTTKDM4E | |
| SCHEMBL25349065 | 0.84 | ADCY1 (0.74) | ADCY1ADCY8SLC2A1HTR2B | |
| SCHEMBL23160941 | 0.82 | ADCY1 (0.71) | ADCY1ADCY8HTR2BKDM4E | |
| SCHEMBL23160940 | 0.81 | ADCY8 (0.68) | ADCY1ADCY8HTR2B | |
| SCHEMBL23160936 | 0.80 | ADCY1 (0.73) | ADCY1ADCY8HTR2B | |
| SCHEMBL20657964 | 0.80 | ADCY1 (0.75) | ADCY1ADCY8HTR2BTDP1MAPT | |
| SCHEMBL23160928 | 0.79 | ADCY1 (0.56) | ADCY1ADCY8SLC2A1HTR2BTDP1 | |
| SCHEMBL23160930 | 0.78 | ADCY1 (0.71) | ADCY1ADCY8HTR2BKDM4E | |
| SCHEMBL23160934 | 0.78 | ADCY1 (0.73) | ADCY1ADCY8HTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690844-B2 | Pyrazolyl pyrimidinone compounds and the uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210100797-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690844-B2 | Pyrazolyl pyrimidinone compounds and the uses thereof | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 9/4885SLC2A1 4314/4885 |
| US-20210100797-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AND THE USES THEREOF | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 9/4885SLC2A1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.